ARIAD Pharma (ARIA) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Chardan Capital Keeps ARIAD (ARIA) at 'Neutral'; Q3 Results Top on Lower R&D Expenses
November 6, 2014 9:10 AM ESTChardan Capital affirms ARIAD Pharma (Nasdaq: ARIA) at Neutral following Q3 results and outlook reported on Wednesday night.
Analyst Ling Wang commented, ARIA reported 3Q14 revenues of $14.7MM, missing consensus estimate of $16.3MM, but in line with our estimate of $14.6MM. 3Q14 EPS of ($0.27) beat both consensus estimate ($0.29) and our estimate ($0.32), due to lower than projected R&D expenses. 3Q14 Iclusig sales were $14.5MM, including sales in the U.S. of $10.5MM and in EU of $4MM. ARIA ended 3Q14 with cash & equivalents of ~$273MM, which should be sufficient to fund operations into... More
